Abstract
This chapter presents literature data on the studies focused on nanoparticulate systems and on pulmonary drugs delivery as a non-invasive alternative for the controlled release of therapeutic agents both in systemic and local treatments. The large lung surface and the existence of minimal barriers that prevent access to pulmonary peripheral make this organ a suitable portal for various therapeutic strategies. The nanotransporters employed in the pulmonary drug delivery provide several advantages, such as the relatively smooth distribution of the drug dose in the alveoli, a better drug solubilisation and the controlled drug release which reduces the administration frequency and decreases the incidence of side-effects. Both the methods of obtaining nanoparticles suitable for improving access to lung peripheral areas and the in vitro/in vivo assessment methods and the toxicity studies have been analyzed.
Keywords: Pulmonary delivery, respiratory apparatus, nanoparticles, lung, alveoli, nebulizer, dry powder inhaler, airway diseases, lung tissue diseases, aerosols, spray-drying, thermal condensation, direct controlled crystallization, liposomes, dendrimers, poly(lactide-co-glicolide), solid-lipid nanoparticles, poly(cyanoacrylate), inertial impaction, gamma scintigraphy.
Related Books
Frontiers in Nano and Micro-Device Design for Applied Nanophotonics, Biophotonics and Nanomedicine
Frontiers in Nanomedicine
Frontiers in Nanomedicine
Nanomaterials and Their Interactive Behavior with Biomolecules, Cells and Tissues
Nanotherapeutic Strategies and New Pharmaceuticals (Part 1)
Nanotherapeutic Strategies and New Pharmaceuticals (Part 2)
On-Chip Pretreatment of Whole Blood by Using MEMS Technology
Toxic Effects of Nanomaterials
Frontiers in Biomaterials
Frontiers in Biomaterials